Yarrow Bioscience exchanges 133,290 common shares for pre-funded warrants
On July 29, 2026, Yarrow Bioscience closed an exchange in which an existing stockholder swapped 133,290 shares of common stock for pre-funded warrants to buy the same number of shares at $0.0001 per share. After the exchange, the company has 2,669,788 common shares and pre-funded warrants for 25,914,530 shares outstanding, so the potential future share count is far larger than the common shares currently outstanding. Shareholders may care because those warrants could add to the number of shares outstanding if exercised.
Key points
- Exchange closed July 29, 2026: 133,290 common shares exchanged for pre-funded warrants at a $0.0001 exercise price
- Pre-funded warrants are immediately exercisable and can be exercised in full, subject to a 9.99% beneficial ownership limit
- Limit may be raised or lowered up to 19.99% on 61 days' notice to the company
- After the exchange: 2,669,788 common shares and pre-funded warrants for 25,914,530 shares outstanding
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.